ArticleAtherosclerosis2025
Claudin 1 dysregulation disrupts coronary microvascular integrity and impairs cardiac function.
Article in Atherosclerosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sexually Dimorphic Regulation of MiR-29a/c-3p in Human Endothelial Cells: Cell Functions and Transcriptome.Journal of cellular physiology · 2026Article
- High dosage lipopolysaccharide-induced duodenal, cecal, hepatic, and cardiac inflammation, programmed cell death, permeability in chicken embryos models.Poultry science · 2025Article
- Integrative Transcriptomic and Epigenomic Profiling for Signature Identification in Coronary Artery Disease: A Pilot Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
aimsClaudin 1 (Cldn1) is a tight junction protein primarily known for its role in epithelial and endothelial barrier function. However, the role of Cldn1 in coronary microvascular barrier remain unclear. The aim of this study is to investigate the biological effects of Cldn1 dysregulation on coronary vascular permeability, inflammation, fibrosis, and left ventricular function.
methodsCldn1 was silenced in human cardiac microvascular endothelial cells (HMVECs) and C57Bl/6 mice using oligonucleotide-based next generation siRNA duplex. Additionally, global transgenic mice with endothelial cell-specific overexpression of Cldn1 were created under the regulation of the CD144 (VE-cadherin) promoter. Permeability was assessed using FITC-dextran assay in vitro and Evans blue dye leakage (Mile's assay) in vivo. Cardiac morphology and function were measured by cardiac MRI, and myocardial pathology was analyzed by immunohistochemistry and Transmission Electron Microscopy (TEM). PCR and Western blotting confirmed Cldn1 expression changes.
resultsCldn1 knockdown reduced protein levels by 46% (p = 0.004) and significantly increased endothelial permeability in HMVEC (p = 0.0007). In mice, Cldn1 knockdown significantly increased Evans blue dye leakage (p = 0.025), macrophage infiltration (p = 0.018), and interstitial collagen (p = 0.048). TEM confirmed endothelial damage particularly affecting the basement membrane structure. Cardiac MRI showed reduced stroke volume (p = 0.004) and ejection fraction (p = 0.043). Cldn1 overexpression reduced vascular permeability (p = 0.002) without altering cardiac function under basal condition.
conclusionCldn1 plays an important role in maintaining coronary microvascular barrier integrity. Its loss leads to increased permeability, inflammation, fibrosis, and impaired cardiac function, while overexpression enhances barrier function without affecting cardiac performance under baseline conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.